EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Placebo‐Referenced Class‐Level Treatment Effects on Chronic Kidney Disease Progression in Patients With Diabetes: A Network Meta‐Analysis

Ravi Kumar Pandey iD, Maryam Imran iD, Ishba Manal iD, Muhammad Ahmad iD, Aliya Noor iD, Ali Rohan iD

Endocrinology, Diabetes & Metabolism · 2026

DOI: 10.1002/edm2.70285 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Endocrinology, Diabetes & Metabolism, 2026. Verfasst von Ravi Kumar Pandey und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nepalgunj Medical College, Nepalgunj, Nepal. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Diabetic Nephropathies, Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Multiple pharmacologic therapies reduce chronic kidney disease (CKD) progression in patients with diabetes; however, the absence of head‐to‐head trials and heterogeneity across studies limits the interpretation of indirect comparisons. We evaluated class‐level treatment effects within a predominantly placebo‐centred evidence network.

Methods

We conducted a systematic review and class‐level frequentist random‐effects network meta‐analysis of randomised controlled trials evaluating major pharmacologic therapy classes for CKD progression in patients with diabetes. The primary outcome was CKD progression, defined according to the principal composite kidney endpoint reported in each trial. Exploratory analyses evaluated albuminuria reduction and trial‐level surrogate associations between albuminuria and clinical kidney outcomes.

Results

Nine trials involving 37,749 participants were included. The evidence network was star‐shaped with placebo as the central comparator. All therapeutic classes were associated with reduced CKD progression compared with placebo. Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) demonstrated the most precise estimate (HR 0.66, 95% CI 0.60–0.74) and were supported by high‐confidence evidence. Confidence in placebo‐referenced estimates for other therapeutic classes ranged from moderate to low because of indirectness, limited trial numbers and differences in study design and patient populations. Findings were generally consistent across sensitivity analyses. No significant association was observed between treatment‐induced albuminuria reduction and clinical kidney outcomes ( R 2 = 0.007), although interpretation was limited by ecological bias and the small number of included studies.

Conclusions

Multiple pharmacologic classes were associated with reduced CKD progression compared with placebo in patients with diabetes. Among placebo‐referenced comparisons, the most consistent and highest‐confidence estimates were observed for SGLT2i. However, the predominantly placebo‐centred network, absence of direct active‐comparator trials and important transitivity concerns limit inference regarding comparative efficacy among therapies. Findings should therefore be interpreted as placebo‐referenced class‐level treatment effects rather than evidence of comparative superiority. Direct comparative effectiveness and combination‐therapy trials are needed to define optimal treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicDiabetic NephropathiesHypoglycemic AgentsDiabetes Mellitus, Type 2HumansDisease ProgressionRandomized Controlled Trials as TopicTreatment OutcomeAlbuminuriaSodium-Glucose Transporter 2 Inhibitors

Stichwörter der Autor:innen

chronic kidney diseasechronic kidney disease progressiondiabetes mellitusdiabetic kidney diseaseend‐stage kidney diseasenetwork meta‐analysissodium‐glucose cotransporter‐2 inhibitors

Substanzen

Hypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Nepalgunj Medical College, Nepalgunj, Nepal.
  • Fatima Jinnah Medical University, Lahore, Pakistan.
  • Dow University of Health Sciences, Karachi, Pakistan.
  • Sharif Medical City, Lahore, Pakistan.
  • King Edward Medical University, Lahore, Pakistan.
  • The University of Lahore, University College of Medicine and Dentistry, Lahore, Pakistan.

ORCID-Profile: Ravi Kumar Pandey, Maryam Imran, Ishba Manal, Muhammad Ahmad, Aliya Noor, Ali Rohan

Zitieren

APA

Pandey, R. K., Imran, M., Manal, I., Ahmad, M., Noor, A., & Rohan, A. (2026). Placebo‐Referenced Class‐Level Treatment Effects on Chronic Kidney Disease Progression in Patients With Diabetes: A Network Meta‐Analysis. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.70285

Vancouver

Pandey RK, Imran M, Manal I, Ahmad M, Noor A, Rohan A. Placebo‐Referenced Class‐Level Treatment Effects on Chronic Kidney Disease Progression in Patients With Diabetes: A Network Meta‐Analysis. Endocrinology, Diabetes & Metabolism. 2026. doi:10.1002/edm2.70285

BibTeX
@article{Pandey2026,
  author = {Pandey, Ravi Kumar and Imran, Maryam and Manal, Ishba and Ahmad, Muhammad and Noor, Aliya and Rohan, Ali},
  title = {Placebo‐Referenced Class‐Level Treatment Effects on Chronic Kidney Disease Progression in Patients With Diabetes: A Network Meta‐Analysis},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2026},
  doi = {10.1002/edm2.70285}
}
Kostenlos starten →